Mucosal healing has emerged as an important therapeutic endpoint in the management of inflammatory bowel disease IBD, but few clinical trials have incorporated it as an outcome, and limited data exist to guide the selection of therapy based on comparative effectiveness in achieving this endpoint.
A recent review of FDA-approved drugs that treat IBD concludes that biologic treatments not only relieve IBD symptoms, they also maintain intestinal health. The study, published on March 22, 2017, in Alimentary Pharmacology & Therapeutics, aimed to examine the efficacy of each therapeutic class of FDA-approved IBD drugs in inducing and maintaining mucosal healing in moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) by performing a meta-analysis of existing data on these therapeutic endpoints.
Researchers led by Aurada Cholapranee, MD, of the Department of Internal Medicine at Montefiore Medical Center, New York, analyzed the following medications: azathioprine (Imuran), methotrexate (Trexall), mercaptopurine (Purinethol), infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia), golimumab (Simponi), natalizumab (Tysabri), and vedolizumab (ENTYVIO). These medications comprise drug classes of immunosuppressive agents, anti-tumor necrosis factor alpha (anti-TNF), and anti-integrin monoclonal antibody therapy.
The meta-analysis was conducted using 12 randomized, controlled trials that included studies of both induction and maintenance for UC and CD. The follow-up durations were 6 to 12 weeks for induction and 32 to 54 weeks for maintenance trials.
The researchers concluded that, in general, the biologic treatments Remicade and Humira, both of which target TNF-alpha, were much more effective at maintaining mucosal healing in CD compared with placebo controls (28% versus 1%, respectively). With respect to UC, medicines targeting both TNFs and integrins (proteins involved in cellular adhesion and stability) were more effective than placebo controls in inducing (45% versus 30%) and maintaining (33% versus 18%) mucosal healing.
The investigators found that in UC, Humira was inferior to Remicade for the induction of mucosal healing; both medications were similar for CD. “We demonstrated that both anti-TNF and anti-integrin biological agents are effective for inducing and maintaining mucosal healing in UC, and anti-TNF therapies in CD,” the authors concluded. But between-drug differences in efficacy do exist within each therapeutic class, they noted, particularly for induction of mucosal healing in UC, with Remicade or combination therapy being the preferred strategy.
The researchers noted that there is an important and urgent need for data demonstrating efficacy of all approved agents in achieving mucosal healing to truly inform comparative effectiveness and patient care to achieve better outcomes.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
Survey of Clinicians: Lower Cost of Biosimilars Is the Main Driver of Treatment Choice in IBD
September 7th 2024Researchers surveyed clinicians from 63 countries and found that adalimumab and infliximab biosimilars, primarily chosen for their lower cost, are widely available and have improved access to biologic treatment in inflammatory bowel disease (IBD).